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Abstract
Background: Immunohistochemical detection of cold shock proteins is predictive for deleterious outcome in
various malignant diseases. We recently described active secretion of a family member, denoted Y-box (YB)
protein-1. We tested the clinical and diagnostic value of YB-1 protein fragment p18 (YB-1/p18) detection in blood
for malignant diseases.
Methods: We used a novel monoclonal anti-YB-1 antibody to detect YB-1/p18 by immunoblotting in plasma
samples of healthy volunteers (n = 33), patients with non-cancerous, mostly inflammatory diseases (n = 60),
hepatocellular carcinoma (HCC; n = 25) and advanced solid tumors (n = 20). YB-1/p18 was then tested in 111
patients with chronic liver diseases, alongside established tumor markers and various diagnostic measures, during
evaluation for potential liver transplantation.
Results: We developed a novel immunoblot to detect the 18 kD fragment of secreted YB-1 in human plasma (YB-1/
p18) that contains the cold-shock domains (CSD) 1-3 of the full-length protein. YB-1/p18 was detected in 11/25 HCC
and 16/20 advanced carcinomas compared to 0/33 healthy volunteers and 10/60 patients with non-cancerous diseases.
In 111 patients with chronic liver disease, YB-1/p18 was detected in 20 samples. Its occurrence was not associated with
advanced Child stages of liver cirrhosis or liver function. In this cohort, YB-1/p18 was not a good marker for HCC, but
proved most powerful in detecting malignancies other than HCC (60% positive) with a lower rate of false-positive
results compared to established tumor markers. Alpha-fetoprotein (AFP) was most sensitive in detecting HCC, but
simultaneous assessment of AFP, CA19-9 and YB-1/p18 improved overall identification of HCC patients.
Conclusions: Plasma YB-1/p18 can identify patients with malignancies, independent of acute inflammation, renal
impairment or liver dysfunction. The detection of YB-1/p18 in human plasma may have potential as a tumor
marker for screening of high-risk populations, e.g. before organ transplantation, and should therefore be evaluated
in larger prospective studies.
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Background
A pivotal role for cold shock proteins has been originally
described in breast cancer, as these proteins relate to cell
transformation and confer aggressive tumor growth [1,2].
The overexpression of one prototypic member of this
evolutionarily conserved protein family, denoted Y-box
(YB) protein-1, in the mammarian gland results in breast
carcinomas with 100% penetrance due to genetic instabil-
ity, mitotic failure and centrosome amplification [2]. It is
known that YB-1 expression levels significantly correlate
with growth “aggressiveness” and consequently with prog-
nosis [3]. Similar studies have been performed with pros-
tate, epithelial ovarian [4], cisplatin-resistant ovarian [5]
and non-small cell lung cancers [6] as well as synovial sar-
comas and osteosarcomas [7]. The uniform finding is a
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correlation of upregulated, mostly nuclear YB-1 expression
with poor outcome, e.g. early relapses and tumor growth,
suggesting high YB-1 expression is an independent nega-
tive prognostic marker for many solid tumors. In particu-
lar, nuclear YB-1 overexpression was associated with more
advanced diseases stages and poor prognosis in hepatocel-
lular carcinoma [8].
Pleiotropic cellular functions have been attributed to
YB-1, including regulation of gene transcription, mRNA
processing, transport and stabilization as well as transla-
tion [9]. Transcription rates of proliferation-associated
genes are upregulated by YB-1, e.g. DNA-polymerase-a
[10], epidermal growth-factor receptor [11], platelet-
derived growth factor [12] and matrix metalloprotei-
nase-2 [13]. YB-1 facilitates wt-p53 binding to DNA
motifs, however not of mutated p53, and represses cell
death-associated fas gene transcription [14]. The YB-1
potency in conferring tumor growth or cell survival is
underscored by in vitro-studies showing that YB-1 acti-
vates the EGFR signaling pathway in human breast
epithelial cells resulting in EGF-independent growth
[15] and epithelial-mesenchymal transition [16]. Adeno-
carcinoma, hepatoma, fibrosarcoma, and colon cancer
cells die with YB-1 knock-down [17,18].
Recent findings from our laboratory indicate addi-
tional extracellular function(s) of YB-1. The protein is
actively secreted by non-transformed and transformed
cells following challenge with cytokines, e.g. PDGF-BB
and TGF-b, and under oxidative stress [19,20]. The
observation was unexpected as YB-1 lacks an N-terminal
signal peptide motif. In this regard, YB-1 has similarities
to other leaderless proteins, including interleukin-1b,
high mobility group box protein (HMGB1) and macro-
phage migratory inhibitory factor (MIF). Besides full-
length YB-1 protein, we observed secreted protein frag-
ments in conditioned cell culture medium [19,20].
The universal role of YB-1 in various solid tumors and
its secretion by tumor cells prompted the current study
in which we tested for the first time the potential clini-
cal and diagnostic value of YB-1 or its fragments in
human plasma in cohorts of healthy volunteers and
patients with malignant as well as non-malignant dis-
eases, using a novel immunoblotting system.
Methods
Study populations
In this survey, five independent cohorts were tested for
the diagnostic value of YB-1/p18 in human plasma: (i)
healthy volunteers (n = 33), (ii) patients with chronic
renal disorders and/or acute infections (n = 60), (iii)
patients with solid tumors with hepatic metastases (n =
20), (iv) patients with known and histologically proven
non-metastasizing hepatocellular carcinoma (n = 25),
and (v) patients with chronic liver diseases (n = 111)
undergoing extensive evaluation before potential liver
transplantation.
The control population comprised 33 healthy blood
donors (19 male, 14 female, median age 39, range 22-67
years) who had normal blood counts, normal amino-
transferase activities and who tested negative for viral
hepatitis markers and HIV. In order to determine renal
function and acute or chronic inflammation as potential
confounding variables for YB-1/p18, 60 patients from
the Nephrology Department (37 male, 23 female, med-
ian 47 age, range 19-84 years) who presented to the
Outpatient Clinic for a follow-up of chronic renal disor-
ders (n = 33, 55%) or who presented due to acute infec-
tions (n = 27, 45%) were included. All populations were
age- and sex-matched with the liver disease study
population.
The liver disease study population consisted of 111
patients (66 male, 45 female, with a median age of 46
years; range 18-70 years) with chronic liver diseases who
were evaluated as inpatients for potential liver transplanta-
tion. Patient data, blood samples and anamnestic informa-
tion were collected prospectively. The study was done
according to the ethical guidelines of the Declaration of
Helsinki, approved by the local ethics committee and after
obtaining written informed consent. The evaluation for a
potential liver transplantation is a highly standardized rou-
tine procedure including a broad variety of clinical, labora-
tory and other diagnostic measures [21]. Furthermore, the
established tumor-markers a-fetoprotein (AFP), carbohy-
drate antigen 19-9 (CA19-9), and carcinoembryonic anti-
gen (CEA) were assessed in all patients.
With regard to the underlying etiology of the liver dis-
ease, patients were assigned to the following groups: (a)
virus hepatitis (n = 32) with chronic hepatitis B (n = 14)
or C (n = 18) virus infection; (b) biliary or autoimmune
(n = 27) with primary (n = 4) or secondary (n = 2) bili-
ary cirrhosis, primary sclerosing cholangitis (n = 17) or
autoimmune hepatitis (n = 4); (c) alcohol-toxic or cryp-
togenic (n = 29) with alcohol-toxic (n = 20) and crypto-
genic (n = 9) cirrhosis; and (d) other origins (n = 23)
with malignant liver tumors (n = 4), liver metastases (n
= 3), liver cysts or benign tumors (n = 5) or hereditary
metabolic or vascular disorders (n = 11). According to
Child-Pugh’s criteria [22], patients were found to have
no cirrhosis (n = 18), Child A (n = 35), B (n = 44) or C
(n = 14) cirrhosis.
Blood samples were collected in EDTA plasma separa-
tor tubes, centrifuged at 2000 × g, and plasma was
stored at -80°C. The scientist who performed the YB-1
blotting was blinded to the samples origin.
Antibodies
Monoclonal antibody generation for YB-1 has recently
been described in detail [23]. Polyclonal antibodies were
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generated by immunization of rabbits with synthesized
polypeptides corresponding to the indicated domains
(details about peptide sequences are available on request)
and affinity purified before usage for immunoblotting.
YB-1 immunoblotting
0.1 μl human plasma was separated on 12.5% SDS-PA
gels, transferred to nitrocellulose, blocked with 2.5%
milk in TBST and incubated overnight at 4°C with the
primary monoclonal anti-YB-1 antibody (biotinylated
Portugal; II 2C-5, 1:1000) [23]. Peroxidase-conjugated
streptavidin (Dianova) and the ECL system (Amersham)
were used for detection.
In each blot, one positive control sample obtained
from a patient with metastasized small cell lung cancer
was run in parallel, that was strongly YB-1/p18 positive.
The YB-1/p18 signals were quantified by densiometry
(NIH imager) and compared to the positive control sig-
nal which was assigned the optical density of “1.0”. The
relative optical density of the sample signals was calcu-
lated accordingly. All samples (patients and controls)
were tested at least on two independent blots, with no
mismatches (one positive, one negative) being detected.
Recombinant YB-1 protein purification and MS/MS
analysis
A pRSET vector (Invitrogen) containing an insert coding
for a hexahistidine T7 epitope-YB-1 fusion protein was a
kind gift from Dr. Chien (University of California, San
Diego). The recombinant YB-1 was synthesized with the
pRSET prokaryotic coding sequence of rat YB-1 (also
denoted EFIA). For expression in Escherichia coli, bac-
teria were induced with isopropyl-b-d-thiogalactoside,
followed by addition of M13/T7 helper phage encoding
T7 polymerase. Expressed protein was released by soni-
cation, and the purification of recombinant YB-1 was
performed with Ni+ affinity columns as outlined by the
manufacturer (Invitrogen). Purity of the expressed YB-1
fusion product was ascertained by analytic SDS-polya-
crylamide gel electrophoresis.
In-gel digest
The bands of interest were excised and in-gel digested in
an adapted manner according to Shevchenko et al. [24].
Mass spectrometric analysis
Dried samples were dissolved in 10 μl 2% ACN/0.1% tri-
fluoroacetic acid (TFA) and applied to an Ultimate 3000
Nano-HPLC (Dionex, Germany), respectively. Each sam-
ple was first trapped on a 1 mm PepMap-trapping col-
umn (Dionex, Germany) for 10 min at 30 μl/min 2%
ACN/0.1% TFA and subsequently subjected to a 75 μm
ID, 5 cm PepMap C18-column (Dionex, Germany). Pep-
tide separation was performed by an ACN- gradient at
300 nl/min. The separation column outlet was online
coupled to a nano-spray interface (Bruker, Germany) of
an Esquire HCT ETDII-Iontrap mass spectrometer (Bru-
ker, Germany). Mass spectra were acquired in positive
MS-mode, tuned for tryptic peptides. MS/MS-precursor
selection was performed in an optimized automatic
regime, with preference for double and triple charged
ions. Every selected precursor was fragmented by colli-
sion induced dissociation (CID) and electron transfer
dissociation (ETD), respectively. MS/MS spectra were
processed by the Data Analysis and BioTools software
from Bruker, Germany. Combined CID/ETD-derived
fragment lists were analyzed by the MASCOT algorithm
on in-house- and swissprot-databases.
Statistics
Results are reported as median and range, and differ-
ences between groups were assessed by Mann-Whitney
U-test, Kruskal-Wallis-ANOVA or chi-square-test [25].
Correlation analyses were performed by Spearman rank
correlation test. Receiver operating characteristic (ROC)
curve analysis and the derived c-statistic were calculated
to assess the accuracy of a marker for predicting an
event [26]. All statistical analyses were performed using
SPSS 12 (SPSS, Chicago, IL, USA).
Results
YB-1 protein complexes are present in plasma samples
To address whether YB-1 protein and fragments thereof
are present in plasma samples of healthy volunteers,
immunoblotting was performed. Diluted plasma samples
were separated by electrophoresis, and protein blots were
incubated with a biotinylated monoclonal anti-YB-1 anti-
body, that has been recently established in our laboratory
[23]. Under non-reducing conditions, full-length YB-1
protein with an approximate size of 50 kDa and a protein
fragment of approximately 30 kDa were detected, further-
more several high molecular weight complexes of more
than 150 kDa (Figure 1A, lane 1). Given the known pro-
pensity of YB-1 to multimerize [9], one explanation may
be the formation of YB-1 homomultimers. Alternatively,
YB-1 protein interactions with other hydrophilic proteins,
e.g. albumin, may explain the existence of such macromo-
lecular complexes. Following incubation of samples with
b-mercaptoethanol and EDTA denoted reducing condi-
tions (R) the high molecular weight complexes were
diminished, and bands corresponding to full-length YB-1
protein as well as the 30 kDa proteolytic fragment were
more pronounced (Figure 1A).
Detection of an 18 kDa YB-1 protein fragment in plasma
samples of cancer patients
The “YB-1” banding pattern obtained with the healthy
control plasma sample was compared with one obtained
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Figure 1 Establishment of a novel immunoblotting assay reveals a characteristic YB-1/p18 fragment in human plasma of cancer
patients. A. Several complexes of molecular sizes >150, 50 and 30 kDa are detected by a monoclonal biotinylated anti-YB-1 antibody in plasma
from a healthy blood donor under non-reducing (NR) conditions (lane 1). Following addition of reducing compounds (R) the high molecular
weight complex is markedly diminished, whereas bands at 66, 50 and 30 kDa are more prominent (lane 3). A similar pattern is detected in
plasma from a patient with lung cancer under non-reducing conditions (lane 5), but reducing conditions reveal an additional band
corresponding to a relative molecular weight of 18 kDa (lane 7). Specificity of the reaction was ensured by omission of the primary antibody (in
lanes 2, 4, 6 and 8). B. In a series of plasma samples obtained from patients with various cancerous diseases, immunoblotting reveals the
presence of a fast migrating band corresponding to 18 kDa (lanes 1 through 8). Specificity of the reaction was confirmed by omission of the
primary antibody (lane 10 vs. 9). C. Schematic overview of YB-1 (also denoted DNA-binding protein B, DbpB) amino acid composition compared
with DbpA. Peptide-derived polyclonal antibodies were generated, as highlighted in the sequence, corresponding to the YB-1 N-terminus (N-
term), C-terminus (C-term) and DbpA N-terminus (N-term). Three polyclonal antibodies were generated against epitopes residing in the cold
shock domain (aa 52-128 of YB-1), denoted CSD1 through 3. D. Immunoblotting was performed with the same plasma sample as in Figure 1A,
using polyclonal, peptide-derived antibodies as depicted in C. YB-1/p18 was visualized with polyclonal antibodies targeting epitopes of the cold
shock domain (CSD) 1 through 3, however not the YB-1- or DbpA-specific antibodies. Also, a 30 kDa signal is detected by the CSD antibodies.
Notably, no DbpA protein was present in the plasma sample. In lane 7, a negative control without primary antibody is shown.
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from plasma of a patient suffering from metastasizing
lung cancer. This did not differ under non-reducing
conditions; however, a faster migrating band of an
approximate molecular mass of 18 kDa appeared under
reducing conditions (Figure 1A). Given this banding pat-
tern difference we collected plasma samples from
patients with various metastatic cancer diseases that ori-
ginated in the breast, larynx, lung, pancreas and rectum.
In all of these samples the 18 kDa band was visualized
by immunoblotting under reducing conditions (Figure
1B), which was denoted “YB-1/p18”. Of note, the full-
length YB-1 protein was detectable in plasma samples of
healthy controls and patients (Figure 1A), and no clear
regulation of the abundantly present full-length YB-1
was noted.
Next, we generated a series of polyclonal, peptide-
derived affinity-purified antibodies in rabbits to map the
domains within the YB-1 protein that correspond to
YB-1/p18. A schematic overview of YB-1 (also denoted
DNA-binding protein B, DbpB) and another member of
this protein family, DbpA, is provided in Figure 1C. Six
different antibodies were generated targeting either the
N- (N-term) or C-terminal (C-term) part of YB-1 or the
N-terminus of DbpA as well as epitopes within the cold
shock domain (CSD1-3) shared by both family members.
By immunoblotting we were able to detect the p18 sig-
nal using polyclonal affinity purified antibodies gener-
ated with peptides CSD1-3, but no band was visualized
with the YB-1 N-term, C-term or DbpA N-term antibo-
dies (Figure 1D). By means of both YB-1 specific (N-
term and C-term) antibodies, full-length YB-1 protein
was detected in plasma samples (~50 kDa; p50) [19],
furthermore bands corresponding to molecular weights
of 66 and 30 kDa were detected. In contrast, the DbpA-
specific antibody did not detect any protein in plasma
samples, although reactivity of the antibody was assured
by testing of nuclear protein extracts prepared with
HepG2 hepatoma cells (data not shown). Therefore, the
YB-1/p18 fragment includes the cold shock, but not the
N- and C-terminal domains.
In order to investigate the identify of the 18-kD-frag-
ment, we have performed ample immunoprecipitation
experiments with the monoclonal as well as the polyclo-
nal antibodies raised against YB-1 epitopes. None of
these experiments were successful in elucidating the
exact fragment composition (data not shown). Moreover,
serum protein precipitation with ammonium sulphate
and enrichment of YB-1/p18 by liquid chromatography
also failed, most likely due to multimerization of the
enriched protein fragment (not shown).
We thus used a different approach to further elucidate
this unexpected banding pattern of YB-1. Recombinant
affinity purified full-length YB-1 protein was subjected
to similar gel electrophoresis and coomassie blue
staining. Without further manipulation and under neu-
tral pH (7.4), there were two dominant bands at about
50 and 25 kDa, alongside several other bands including
one at 66 kDa and the p18 band (Figure 2A). To ascer-
tain that these bands of interest matching the signals
from human plasma are all derivatives of the His-tagged
recombinant protein, MS/MS analysis was performed on
excised bands (Figure 2B). Interestingly, also the band
running at 66 kDa only contains YB-1 protein, thereby
likely reflecting dimers of different YB-1 fragments (Fig-
ure 2B-1). The band at 18 kDa was identified as trun-
cated cold-shock domain with peptides corresponding
to aa81-137 (Figure 2B-4). This is in full agreement with
the findings obtained from plasma samples using the
polyclonal and monoclonal YB-1 antibodies. Given the
use of an expression plasmid with non-existing alterna-
tive splice sites and the expression in bacteria, it appears
likely that YB-1/p18 is generated as an (auto-)proteolytic
fragment.
YB-1/p18 is a biomarker for cancers from different origin,
independent of inflammation or renal failure
The initial observation of the YB-1/p18 signal in cancer
plasma samples raised the question whether this proteo-
lytic YB-1 protein fragment is specifically present in
cancer disease. Plasma samples from 33 healthy blood
donors were assayed for the presence of YB-1/p18.
None of the healthy blood donor plasma samples tested
strongly positive for the YB-1/p18 fragment (Figure 3A).
Furthermore, a series of 60 plasma samples was col-
lected from outpatients with chronic renal disorders (n
= 33) and/or acute inflammatory diseases (n = 27, e.g.
urinary tract infection or pneumonia). YB-1/p18 and
corresponding markers of inflammation (e.g. WBC
count, procalcitonin, C-reactive protein) as well as renal
function (e.g. glomerular filtration rate, serum creati-
nine) were determined. YB-1/p18 bands were prominent
in 5 out of 60 patients (8%), weakly present in 5 more
patients (8%) and absent in the remainder 50 patients
(84%). Importantly, there was no association of inflam-
matory marker levels or impairment of renal function
with the presence of YB-1/p18 (U-test and Spearman
rank correlation analysis, Figure 3B). Given these results,
we assigned YB-1/p18 positivity in a sample, if the rela-
tive optical density (OD) exceeded 0.45 (as compared to
the positive control carried in each blot with an arbi-
trary OD of 1.0).
To further elaborate on the detection of YB-1/p18 in
various cancer diseases, plasma samples were analyzed
from two cohorts of patients: metastatic disease of solid
tumors, all demonstrating hepatic filiae, and patients
with non-metastasizing hepatocellular carcinoma (HCC).
YB-1/p18 was detected in 11 out of 25 (44%) of all
patients with HCC (Figure 3C). Moreover, YB-1/p18
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was present in 16 out of 20 plasma samples (80%) col-
lected from individual patients with different metastasiz-
ing cancers (Figure 3D).
YB-1/p18 is not associated with the severity of liver
cirrhosis in patients with chronic liver disease
These data indicated that YB-1/p18 positivity may be a
biomarker to identify cancer disease for screening pur-
poses. We therefore included YB-1/p18 immunoblotting
in a cohort of patients with chronic liver disease, a
condition which predisposes to malignancies. These
patients had not been diagnosed with cancer disease at
study entry. All of them underwent most extensive clini-
cal, radiologic/technical as well as laboratory examina-
tions, because they were evaluated for potential liver
transplantation (Table 1). Among all patients, 20/111
(18%) showed positivity for YB-1/p18 by immunoblot-
ting, as exemplified in Figure 4A. Positivity for YB-1/
p18 was not associated with advanced stages B and C of
liver cirrhosis, as assessed by Child-Pugh’s score (Table
Figure 2 YB-1 protein spontaneously forms fragments and multimers. A. Recombinant affinity-purified YB-1 protein was subjected to gel
electrophoresis and coomassie blue staining (lane 1, marker; lane 2, coomassie) revealing the spontaneous formation of signals at different sizes
(1: 66 kDa, 2: ~50 kDa, 3: ~25 kDa, 4: 18 kDa). Lane 3 displays an immunoblot of the same recombinant protein preparation with T7-tag-antibody
directed against the T7-tag at the N-terminus of the protein. B. Bands from electrophoresis of recombinant YB-1 protein (as shown in A) were
excised and subjected to MS/MS analysis. The results of protein sequencing for the signals of interest (1-4) are shown.
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Figure 3 YB-1/p18 is largely absent in plasma samples of healthy blood donors, patients with inflammatory and renal diseases, but
found in metastatic cancerous diseases and hepatocellular carcinoma. A. Plasma samples from 33 healthy blood donors were analyzed for
the presence of YB-1/p18. In none of these samples YB-1/p18 was present (representative blots are shown). Positive control plasma from cancer
patient is indicated by “+”. The relative optical density (OD) assessed by densiometry is given. Positivity was considered, if relative OD > 0.45. In
each blot, one positive control sample obtained from a patient with metastasized small cell lung cancer was run in parallel, that was strongly
YB-1/p18 positive. The YB-1/p18 signals were quantified by densiometry (NIH imager) and compared to the positive control signal which was
assigned the optical density of “1.0”. The relative optical density of the sample signals was calculated accordingly. B. Analysis of 60 plasma
samples collected from patients with various underlying, non-cancerous diseases was performed for the presence of YB-1/p18. Corresponding C-
reactive protein (CRP) and creatinine levels are provided for each patient. Representative blots are shown. C. Immunoblotting with biotinylated
monoclonal anti-YB-1 antibody was performed for YB-1/p18 in 25 individual patients with primary hepatocellular carcinoma (HCC).
Representative blots are shown. D. Immunoblotting with biotinylated monoclonal anti-YB-1 antibody was performed for YB-1/p18 in 20
individual patients with various advanced cancer diseases and liver metastases. Representative blots are shown.
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1). Furthermore, plasma YB-1/p18 detection did not
correlate with markers of liver function (data not
shown).
Subgroups of the study cohort showed differences in
the detection of YB-1/p18. In patients with virus hepati-
tis, only 2/32 (6%) tested YB-1/p18 positive. Patients
with biliary liver diseases (22%), alcoholic cirrhosis
(21%) or other liver diseases (26%) showed YB-1/p18
positivity in significantly more patients (p = 0.031, chi2-
test).
Sensitivity and specificity of YB-1/p18 and other tumor
markers for hepatocellular carcinoma
We hypothesized that these differences for plasma YB-1/
p18 in the subgroups may be due to a different preva-
lence of malignancies. Out of 111 patients, 15 (14%)
were diagnosed with HCC during evaluation, confirmed
by histology. From these, 20% tested positive for YB-1/
p18 (Table 2A). In comparison, 6 (40%) of all HCC
patients tested positive for AFP (defined as AFP > 15
μg/L), 5 (33%) for CA19-9 (>37kU/L) and none for CEA
(>5 μg/L). Of note, the combined assessment of HCC by
CA19-9 and AFP determinations identified 8 out of 15
patients (53%). Two of the remainder 7 patients with
HCC were positive for YB-1/p18. Thus, the inclusion of
YB-1/p18 to the routine tumor markers would have
raised the number of identified cases to 10 out of 15
(67%), although it does not have a high sensitivity to
detect HCC by itself. Moreover, only one HCC patient
tested positive for AFP and YB-1/p18, indicating that
the combination of both markers is not likely to
improve diagnostic accuracy. As mentioned above, 44%
of samples from a different (independent), retrospec-
tively analyzed cohort of patients with established, histo-
logically proven HCC were positive for YB-1/p18
(Figure 3C).
As the total population of patients was rather hetero-
geneous, we further investigated the subgroup of
patients with chronic virus hepatitis to assess the
specificity of the tumor markers. It is known that in
conditions of chronic liver inflammation with regenera-
tive processes AFP levels may be elevated [27,28].
Furthermore, cholestasis may result in increased plasma
levels of CA19-9 [29,30]. In fact, up to 40% of cirrhotic
patients may test positive for CEA [31] and up to 70%
for CA19-9 [32], without any evidence of cancer. In our
study population 23 patients exhibited chronic virus
hepatitis but had no clinical, pathological or radiomor-
phological signs of HCC or other malignancies. Among
these, only 1 (4%) tested YB-1/p18 positive, whereas 4
(17%) were positive for AFP, 13 (57%) for CA19-9 and 5
(22%) for CEA. Thus, AFP, CA19-9 and CEA have a
higher rate of false-positive results compared to YB-1/
p18 in this cohort.
YB-1/p18 is a sensitive marker to detect malignancies
other than HCC
Out of 111 patients included in our study, 5 were diag-
nosed with other malignancies, that were liver metas-
tases of a neuroendocrine pancreatic tumor (n = 3),
cholangiocellular carcinoma (n = 1) and B-cell type
non-hodgkin lymphoma (n = 1). Out of these patients, 3
(60%) tested positive for YB-1/p18. In contrast, 1/5
tested positive for AFP (20%), 4/5 (80%) for CA19-9,
and none (0%) for CEA. As mentioned above, one of
the YB-1/p18 negative patients was diagnosed with non-
hodgkin lymphoma. He had been treated by radiother-
apy with curative intention prior to inclusion into the
study and may be regarded as being in remission, thus
expected to test negative for tumor markers (Table 2B).
Receiver operating characteristic (ROC) curve analyses
were performed to assess the diagnostic value of YB-1
and the other tumor markers in identifying patients
with either HCC or other malignancies (Figure 4). For
patients with chronic liver diseases and HCC, AFP was
found to be the best single predictive marker with a c-
statistic (AUC, area under the curve) of 0.668. YB-1/p18
(c = 0.511), CA19-9 (c = 0.404) and CEA (c = 0.411)
Table 1 Characteristics of the patients with chronic liver diseases
All patients Stages of cirrhosis
no cirrh. Child A Child B Child C
[n] 111 18 35 44 14
Sex (male/female) [n] 66/45 11/7 18/17 30/14 7/7
Age [years] median (range) 46 (18-70) 46 (18-65) 41 (18-64) 48 (20-70) 40 (26-69)
Etiology of liver disease [n]
Virus hepatitis 32 (29%) 1 (6%) 9 (26%) 17 (39%) 5 (36%)
Biliary or autoimmune 27 (24%) 1 (6%) 14 (40%) 10 (23%) 2 (14%)
Alcohol or cryptogenic 29 (26%) 1 (6%) 11 (31%) 10 (23%) 7 (50%)
Other origin 23 (21%) 15 (83%) 1 (3%) 7 (16%) 0 (0%)
YB-1/p18 positivity [n] 20 (18%) 6 (33%) 7 (25%) 5 (11%) 2 (14%)
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Figure 4 YB-1/p18 identifies malignancies other than HCC in patients with chronic liver disease. A. Representative Western Blot for YB-1
from patients’ plasma showing a specific signal at 18 kDa. The patient’s number is given; #74 had hepatitis C virus related HCC, #75 alcohol-
toxic cirrhosis, #76 alcohol-toxic cirrhosis and HCC, #78 had hepatitis C virus infection and cirrhosis without HCC, #79 had primary sclerosing
cholangitis. Patient #77 had a pancreatic neuroendocrine tumor with hepatic metastases. Plasma from a patient with small cell lung cancer
served as a positive control (lane 7). The relative optical density (OD) assessed by densiometry is given. Positivity was considered, if relative OD >
0.45. B. Receiver operating characteristic (ROC) analysis shows that positivity for AFP (area under the curve, AUC: 0.668) was superior to YB-1/p18
(0.511), CA 19-9 (0.404) and CEA (0.411) in identifying patients with HCC among chronic liver disease patients. C. In contrast, positivity for YB-1/
p18 (AUC: 0.719) was the best predictor for other malignancies in the study population by ROC analysis, whereas AFP (0.548), CA 19-9 (0.657) or
CEA (0.419) were less powerful.
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were less powerful in the diagnosis of HCC (Figure 4B).
In contrast, YB-1/p18 was the best single marker (c =
0.719) to identify patients with other malignancies
among our study population (Figure 4C) and proved
superiority compared with AFP (c = 0.548), CA19-9 (c =
0.657) or CEA (c = 0.419). However, it is important to
note that other malignancies than HCC occurred rarely
in our cohort, which limits the exact determination of
sensitivity/specificity for detecting malignancies other
than HCC for the tumor markers investigated.
Analysis of ‘non-tumorous’ YB-1/p18 positive patients
14 out of 111 patients had detectable YB-1/p18 plasma
levels without apparent tumor disease at the time of
investigation. However, in one patient, HCC was diag-
nosed in follow-up examinations within three months.
3/14 patients were diagnosed with primary sclerosing
cholangitis, that has a high risk for the development of
cholangiocellular carcinoma, reaching 15% [33]. Thus, it
is likely that some of the 14/111 YB-1/p18-positive
patients without diagnosed tumor could indeed have
had an underlying, ‘subclinical’ malignancy. However, a
comprehensive analysis of the predictive value of YB-1/
p18 is hampered by (a) relatively small study cohort (n
= 111) with a rare incidence of new malignancies, and
(b) short follow-up of the very high-risk patients due to
the fact that these patients received liver transplantation
on average within 6-12 months after evaluation [34].
Discussion
In this work, we identified circulating 18 kDa fragments of
YB-1 protein (YB-1/p18) in human plasma using immuno-
blotting with a monoclonal antibody. The presence of YB-
1/p18 in plasma samples may indicate malignant disorders
of different origin. We found YB-1/p18 in about 80% of
patients with advanced carcinomas and hepatic metas-
tases, but in none of healthy volunteers. Potential con-
founding variables such as acute inflammations, renal or
hepatic dysfunction could be excluded in non-cancerous
cohorts. In a very well characterized group of 111 patients
with chronic liver diseases, YB-1/p18 had a high sensitivity
and reasonable specificity to identify patients with malig-
nant tumors, suggesting its clinical potential as a tumor
marker for screening ‘high-risk’ patient populations.
Table 2 Characteristics of the chronic liver disease patients with malignancies
A. Patients with hepatocellular carcinoma (HCC)



















9 primary 111 5 7.2 623 ++ 2 2 pos. ++
15 HCV 525 ++ 17 ++ 4.1 4 2 276 ++ neg.
16 HCV 230 5 6.2 1023 ++ 1 10 neg.
17 HCV 162 5 2.8 87 ++ 2 59 ++ neg.
27 primary 179 5 6.6 12598 ++ 4 49 ++ neg.
38 HCV 211 5 5.1 9 3 36 neg.
49 HCV 254 ++ 5 3.7 6 3 100 ++ neg.
51 primary 136 5 4.1 4 1 17 neg.
59 alcohol 194 9 ++ 5.3 1 1 16 pos. ++
66 alcohol 182 5 3.8 155 ++ 3 50 ++ neg.
74 HCV 187 5 4.0 15 2 30 neg.
76 alcohol 235 11 ++ 4.3 208 ++ 1 14 neg.
86 HCV 184 5 3.4 6 1 34 pos. ++
88 unknown 175 7 ++ 7.2 4 2 16 neg.
107 HCV 548 ++ 5 5.7 10 1 28 neg.
B. Patients with malignancies other than HCC



















41 PNET 288 ++ 31 ++ 9.7 5 1 363 ++ neg.
50 PNET 121 5 7.2 5 1 8 pos. ++
53 CCC 206 7 ++ 5.8 9 4 177 ++ pos. ++
77 PNET 97 6 ++ 4.4 3 1 84 ++ pos. ++
90 NHL * 234 5 2.7 40 ++ 4 257 ++ neg.
HCV, Hepatitis C virus infection; PNET, pancreatic neuroendocrine tumor; CCC, cholangiocellular carcinoma; NHL, non-hodgkin lymphoma.
*Patient received prior curative radiotherapy.
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Although many ‘tumor markers’ are widely used in
monitoring cancer patients during therapeutic interven-
tions, lack of sensitivity and specificity preclude the use
of most existing markers for the early detection of
malignancy [35]. The clinically best established general
screening tumor marker at present is prostate-specific
antigen (PSA), which is considered a specific indicator
of prostate cancer, but still about 15% of ‘PSA-negative’
men have biopsy-detected prostate cancer [36].
However, some markers can be useful in patient
cohorts at high risk of developing certain carcinomas, e.
g. AFP in patients with chronic virus hepatitis or liver
cirrhosis at risk for HCC [28]. Several new markers have
been suggested that could, alone or in combination with
AFP, improve the accuracy of diagnosing HCC, such as
AFP-L3, DCP/PIVKAII, CA242 or AAG [37-40]. In our
study, AFP proved again to be superior in detecting
HCC compared with CEA, CA19-9 and YB-1/p18 (Fig-
ure 4B). However, AFP or other ‘established’ markers
were not powerful as screening tools for malignancies
other than HCC. In fact, AFP and especially CEA or
CA19-9 were elevated in a high number of patients with
viral hepatitis without detectable malignancy, in line
with previous reports [31,32]. YB-1/p18, on the other
hand, was independent of the degree of liver cirrhosis
and had a low rate of ‘false-positive’ results in liver dis-
ease patients as well as in patients with acute inflamma-
tory or renal diseases, suggesting its usefulness in
principle as a screening tool. YB-1/p18 furthermore
tested negative in all blood donors (’healthy controls’)
and was not associated with inflammation or renal
impairment (’non-malignant control patients’); all con-
trol populations were strictly age- and sex-matched to
the liver patient cohort (Figure 3). In contrast to YB-1/
p18, renal function is a well appreciated confounding
variable for most established tumor markers [41,42].
YB-1/p18 was more powerful in detecting malignan-
cies other than HCC compared to AFP, CEA or CA19-9
in patients with chronic liver disease (Figure 4C), and
patients with a variety of malignancies with liver metas-
tases tested predominantly positive for YB-1/p18 (Figure
1B, 3C). The relatively high sensitivity of YB-1/p18 for
various malignant disorders may be explained by its
unique role in tumor biology. Nuclear YB-1 overexpres-
sion is a common finding in a variety of solid tumors,
including breast, prostate, ovarian or lung cancer [4-7],
and has been linked to tumor growth and survival of
cancer patients in several studies. At present, it is
unclear whether the detection of extracellular (circulat-
ing) YB-1/p18 fragment is associated with nuclear YB-1
overexpression in tumors. We therefore collected tumor
tissue specimens (n = 20) and determined the subcellu-
lar YB-1 localization with monoclonal antibody by
immunohistochemistry. At the same time we have
determined the presence or absence of YB-1/p18 in cor-
responding serum samples. As a result, we were not
able to find a positive correlation (unpublished observa-
tions). However, future studies will have to confirm
these preliminary observations.
YB-1 appears to fulfill critical cellular functions such
as transcriptional upregulation of proliferation-asso-
ciated and downregulation of apoptosis-related genes
or induction of drug-transporter genes (like MDR-1)
involved in chemoresistance [1,7]. The exact function
of extracellular YB-1 remains to be elucidated; how-
ever, by adding recombinant YB-1 protein to cell-lines
in vitro we were able to demonstrate a profound pro-
mitogenic effect, suggesting that secreted YB-1 frag-
ments could act as a tumor growth-promoting factor
[19]. Besides the abundant presence of full-length YB-1
protein with a relative mobility corresponding to 50
kDa in SDS-PAGEs that was detected in all (healthy,
non-malignant, malignant) plasma samples, the YB-1
fragment identified here, corresponding to a relative
MW of ~18 kDa (denoted YB-1/p18) and harboring
the evolutionarily conserved cold shock domain
appears to be associated with the presence of malig-
nant disease. Antibody and MS/MS mapping of differ-
ent recombinant YB-1 protein derivatives confirmed
the cold-shock domain identity of the 18 kDa fragment
(Figure 2). However, it is currently unclear whether
YB-1/p18 is released from the tumor cells or from
infiltrating stromal cells. Our own experiments indi-
cated that YB-1 processing may occur intracellularly
within the vesicles that release YB-1 from the cells, but
it is unknown whether this is a phenomenon of cancer
and transformed cells only [19].
At present, the detection of YB-1/p18 can only be
regarded as a “qualitative” tumor phenomenon, because
we failed to quantitatively relate YB-1/p18 in plasma to
either total full-length YB-1 in plasma or to nuclear YB-
1 expression in the tumor (not shown). The develop-
ment of a specific ELISA system for YB-1/p18 may in
the future allow to more quantitatively measure YB-1/
p18 levels. With such a more accurate quantification
tool, new quantitative associations (e.g., between full-
length YB-1 in plasma or nuclear YB-1 expression
levels) may be explored.
Given our promising results, we set out to prospec-
tively evaluate the clinical use of YB-1/p18 in larger
cohorts of patients with diagnosed malignant disease. In
patients with various solid or hematological malignan-
cies, YB-1/p18 is detected in more than 75% of cancer
patients (FT, NK, PRM, unpublished observations).
Tumor-specific factors (origin, staging, grading, tumor
mass, response to treatment) are currently evaluated for
their impact on YB-1/p18. The presented results suggest
that YB-1/p18 should be further investigated as a
Tacke et al. BMC Cancer 2011, 11:185
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potential screening biomarker for malignant diseases,
preferably in high-risk patient populations.
Conclusions
The secreted 18 kD fragment of the cold shock protein
YB-1, YB-1/p18, can be reliably detected in human
plasma of patients with advanced cancerous diseases,
using a novel immunoblot assay. Our study suggests
that plasma YB-1/p18 might bear diagnostic potential to
identify patients with malignancies, independent of
acute inflammation, renal impairment or liver dysfunc-
tion. The detection of YB-1/p18 in human plasma may
have potential as a tumor marker for screening of high-
risk populations, e.g. before organ transplantation, and
should therefore be evaluated in larger prospective
studies.
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